This announcement is a separate document:
科濟藥業-B：自願公告 - CT071已獲得FDA的IND批准用於治療復發/難治多發性骨髓瘤或復發/難治原發性漿細胞白血病
CARSGEN-B: VOLUNTARY ANNOUNCEMENT - CT071 RECEIVED IND CLEARANCE FROM THE FDA FOR THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA OR RELAPSED/REFRACTORY PRIMARY PLASMA CELL LEUKEMIA
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.